


Preclinical accomplishments towards further PK and pre-IND - IND


Ocular Delivery Results (Biodistribution Studies)

Our recent study confirms the successful biodistribution of a Cy3-labeled compound across key rabbit ocular tissues using both intravitreal and topical delivery routes. The compound demonstrated excellent tolerability, with no adverse effects or tissue changes observed. Intravitreal delivery achieved strong fluorescence in the retina, ciliary body, and Descemet's membrane, confirming deep ocular penetration. Notably, topical administration also enabled compound penetration into the cornea-limbus region, highlighting its potential as a noninvasive ocular delivery approach.

Rabbit Retina. A strong fluorescent signal in various cell layers of the retina after IVT administration. Cy3 (red), DAPI (blue).



Rabbit Ciliary Body. Strong Cy3 signal after IVT administration in the ciliary body epithelium (arrow). Cy3 (red), DAPI (blue).



Breakthrough in Glaucoma Innovation (Acute Efficacy Studies)

We're excited to announce a major advance in our mission to transform glaucoma treatment. Our most recent independently conducted preclinical study delivered **exceptional results**, revealing a **novel mechanism of action** that sets our program apart from all existing therapies.

Key Findings:

- ⊞ **Significant, sustained IOP reduction** in both eyes via intravitreal and topical delivery.
- ⊞ **Dual-route efficacy—a first-of-its-kind result** in glaucoma research.

Next Steps:


- ⊞ Launch a **chronic glaucoma study** focused on long-term pressure control and RGC protection.
- ⊞ Engage with the FDA in a pre-IND meeting to advance our clinical development roadmap.

These results mark a bold step toward **the first truly disease-modifying therapy for glaucoma**, with the potential to preserve vision for millions of patients worldwide.

Strengthening Our Intellectual Property Position

We're thrilled to announce the provisional filing of new intellectual property protecting our breakthrough glaucoma formulations: peptide nanostructures featuring a proprietary ocular epitope and their therapeutic applications (*Priority Date: September 8, 2025*).

Achieved in collaboration with our IP counsel at Wilson Sonsini, this filing further reinforces our leadership in next-generation glaucoma therapeutics and strengthens the foundation for long-term commercial exclusivity.




Human trabecular meshwork cells were treated with our Cy3-labeled glaucoma-targeting nanostructures for 4 hours. The cells were fixed and immunostained for the lysosomal marker LAMP2 (green) and the actin-associated protein smooth muscle actin (SMA; cyan). Nuclei were counterstained with DAPI, shown in gray (pseudocolor). Note the internalization of our nanostructures within the cellular body (arrows).

CADE Prize Recognition

About the CADE Prize for Inventivity

Since 2010, the Cade Prize for Inventivity has celebrated American Innovation by identifying, recognizing, and celebrating inventors and entrepreneurs who creatively apply science and innovative technology to solve meaningful problems. The Cade Prize has attracted hundreds of creative thinkers from diverse sectors who have shared their cutting-edge inventions with real-world market potential.



2025 Competition

100 Applications
16 States

CADE Prize Recognition: A Milestone for NanoNeurosciences

We're proud to announce that NanoNeurosciences was selected as one of 15 national finalists for the prestigious Cade Prize for Inventivity, selected from more than 100 applicants across 16 states.

This recognition marks an important milestone in our journey - a tremendous honor and an external validation of our innovation and transformative potential of our work in nanomedicine.



Winning 1st place in Healthcare Category

NanoNeurosciences is honored to have achieved **1st place nationally in the Healthcare category**, underscoring our commitment to innovation at the intersection of nanotechnology and neuroscience. This recognition highlights our team's dedication to advancing precision medicine and developing groundbreaking solutions for neurological health. We are honored to lead the way in transforming healthcare through cutting-edge research and impactful applications that aim to improve lives.

Winning 1st place in the Healthcare category, reaffirms the strength of our scientific approach and the promise of our platform. This distinction not only celebrates our team's creativity and dedication but also amplifies our work on a national scale, helping us to open doors to new opportunities, partnerships, and resources, and strengthening our resolve to push the boundaries of science and technology towards real-world impact.

We extend our sincere gratitude to the Cade Prize committee, judges and organizers and were deeply honored to connect with visionary leaders such as NVIDIA's co-founder (Chris Malachowsky) during the event.

BioInnovation Greece Event

NNS board participated in Bio3-2025 in Athens connecting with Greece's biotech ecosystem.

We shared our vision and explored new collaborations. Grateful to BioInnovation Greece for an inspiring forum advancing biotechnology, bioinformatics & the bioeconomy.



from left to right

A. Papamichos
Chairman & Co-Founder

G. P. Diantzikis
CFO & Co-Founder

G. Roumeliotis
Strategic Advisor



bio³25

2025 Bio3 Forum

Biotechnology, Bioinformatics &
Bioeconomy Forum: Fostering
Collaboration in Industry &
Academia September 15-19, 2025
Technopolis, Gazi, Athens, Greece



Industry news

The peptide therapeutics field continues to advance across multiple disease areas. Novartis has expanded its collaboration with PeptiDream to develop targeted *radiotherapy treatments for cancer*, underscoring the growing role of precision peptide platforms in oncology. In metabolic diseases, Novo Nordisk's obesity drug Wegovy continues to drive record market growth, while researchers have identified a novel enzyme, PapB, that could enhance the *stability of peptide-based drugs* for diabetes and obesity.

Meanwhile, Orbis Medicines has launched with a €26 million seed round to develop *oral peptide therapies*, signaling strong investor confidence in next-generation delivery technologies. Beyond metabolic and cancer applications, researchers are also exploring peptide compounds for *neurological and addiction-related disorders*, including a promising candidate shown to reduce opioid cravings, according to Syracuse University Today.

 info@nanoneurosciences.com



NanoNeurosciences Research & Development Laboratory:
UF Innovate at Sid Martin, 12085 Research Dr, Lab # 130, Alachua, FL 32615, USA



www.nanoneurosciences.com